Summary:
Waypoint Bio relocates to the Alexandria Center for Life Science in NYC.
The startup specializes in drug discovery using AI and spatial biology.
Co-founders Xinchen Wang and David Phizicky raised $14.5 million in seed funding.
The new lab space spans 3,413 square feet at 430 East 29th St.
JLL's Thomas Burrus facilitated the lease agreement.
Waypoint Bio, a pioneering spatial biology startup, is making waves by relocating to the Alexandria Center for Life Science in New York City. The company has signed a lease for 3,413 square feet of lab and office space at 430 East 29th St., previously operating from the Biolabs Incubator.
Founded in 2021, Waypoint Bio aims to leverage AI, pooled screening, and spatial biology to enhance drug discovery processes. The co-founders, Xinchen Wang and David Phizicky, both MIT alumni, have raised $14.5 million in seed funding to develop CAR-T cell therapies targeting cancer and autoimmune diseases. Wang expressed excitement about their new location, stating, "The Alexandria Center for Life Science is a one-of-a-kind home to world-class pharmaceutical and biotechnology companies."
The Alexandria Center is recognized for fostering innovation within New York City's life science ecosystem, providing a collaborative environment and proximity to leading academic medical institutions. Thomas Burrus, JLL Associate Vice President, represented Waypoint Bio in this strategic move, highlighting the growing demand for specialized lab spaces in the area.
About Waypoint Bio
Waypoint Bio is at the forefront of biotechnology, focusing on novel cell therapies for solid tumors through its proprietary spatial pooled screening technology. The company has quickly established itself within the biotech community, assembling a team of experts and securing significant funding to propel its mission.
About JLL
JLL is a global leader in commercial real estate, helping clients navigate their property needs for over 200 years. With a strong presence in New York's commercial real estate market, JLL continues to support innovative companies like Waypoint Bio in their growth and development.
Comments